vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1202Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEКОМПЛЕКСНАЯ ТЕРАПИЯ ИНФЕКЦИИ HELICOBACTER PYLORI В ДЕТСКОМ ВОЗРАСТЕ С ИСПОЛЬЗОВАНИЕМ РИФАКСИМИНАCOMPLEX TREATMENT OF HELICOBACTER PYLORI INFECTION WITH RIFAXIMIN IN CHILDRENНижевичА.А.NizhevichA.A.ЩербаковП.Л.ShcherbakovP.L.АхмадееваЭ.Н.AkhmadeevaE.N.СатаевВ.У.SataevV.U.ХасановР.Ш.KhasanovR.Sh.Башкирский государственный медицинский университет, УфаРоссияBashkiria State Medical University, UfaRussian FederationЦентральный НИИ гастроэнтерологии, МоскваРоссияCentral Scientific Institute of Gastroenterology, MoscowRussian FederationРеспубликанская детская клиническая больница, УфаРоссияRepublic Children’s Clinical Hospital, UfaRussian Federation20092409201586Вопросы современной педиатрии106108Copyright © Нижевич А., Щербаков П., Ахмадеева Э., Сатаев В., Хасанов Р., 20092009Нижевич А., Щербаков П., Ахмадеева Э., Сатаев В., Хасанов Р.Nizhevich A., Shcherbakov P., Akhmadeeva E., Sataev V., Khasanov R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1202ReferencesScarpignato C. Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig. Liver. Dis. 2004; 36: 243–247.Scarpignato C. Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig. Liver. Dis. 2004; 36: 243–247.Щербаков П.Л., Корсунский А.А., Филин В.А., Цветкова Л.Н. Новые подходы к диагностике и лечению инфекции H. pylori у детей. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2001; 11 (приложение 13): 116–118.Щербаков П.Л., Корсунский А.А., Филин В.А., Цветкова Л.Н. Новые подходы к диагностике и лечению инфекции H. pylori у детей. Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2001; 11 (приложение 13): 116–118.Nakayama Y., Graham D. Helicobacter pylori infection: diagnosis and treatment. Expert Rev. Anti–infect. Ther. 2004; 2: 599–610.Nakayama Y., Graham D. Helicobacter pylori infection: diagnosis and treatment. Expert Rev. Anti–infect. Ther. 2004; 2: 599–610.Хомерики Н.М., Хомерики С.Г. Некоторые механизмы развития побочных эффектов антихеликобактерной терапии и пути их коррекции. Consilium medicum. 2005; 2 (приложение): 22–25.Хомерики Н.М., Хомерики С.Г. Некоторые механизмы развития побочных эффектов антихеликобактерной терапии и пути их коррекции. Consilium medicum. 2005; 2 (приложение): 22–25.Holton J., Vaira D., Menegatti M., Barbara L. The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J. Antimicrob. Chemother. 1995; 35: 545–549.Holton J., Vaira D., Menegatti M., Barbara L. The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J. Antimicrob. Chemother. 1995; 35: 545–549.Fujimura S., Kato S., Kawamura T., Watanabe A. In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults. J. Antimicrob. Chemother. 2002; 49: 541–543.Fujimura S., Kato S., Kawamura T., Watanabe A. In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults. J. Antimicrob. Chemother. 2002; 49: 541–543.Venturini A.P. Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. Chemotherapy. 1983; 29: 1–3.Venturini A.P. Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. Chemotherapy. 1983; 29: 1–3.Scarpignato C., Pelosini I. Bismuth compounds for eradication of Helicobacter pylori: pharmacology and safety. Progr. Basic. Clin. Pharmacol. 1999; 11: 87–126.Scarpignato C., Pelosini I. Bismuth compounds for eradication of Helicobacter pylori: pharmacology and safety. Progr. Basic. Clin. Pharmacol. 1999; 11: 87–126.Scarpignato C. Pelosini I. Antisecretory drugs for eradication of Helicobacter pylori: antibacterial activity and synergism with antimicrobial agents. Progr. Basic. Clin. Pharmacol. 1999; 11: 136–180.Scarpignato C. Pelosini I. Antisecretory drugs for eradication of Helicobacter pylori: antibacterial activity and synergism with antimicrobial agents. Progr. Basic. Clin. Pharmacol. 1999; 11: 136–180.Quesada M., Sanfeliu I., Junqvera F. et al. Evaluation of Helicobacter pylori susceptibility to rifaximin. Gastroenterol. Hepatol. 2004; 27: 393–396.Quesada M., Sanfeliu I., Junqvera F. et al. Evaluation of Helicobacter pylori susceptibility to rifaximin. Gastroenterol. Hepatol. 2004; 27: 393–396.Pretolani S., Bonvicini F., Brocci E. et al. Effect of rifaximin, a new non-absorbed antibiotic, in the treatment of Helicobacter pylori infection. Acta Gastroenterol. Belg. 1993; 56: 144.Pretolani S., Bonvicini F., Brocci E. et al. Effect of rifaximin, a new non-absorbed antibiotic, in the treatment of Helicobacter pylori infection. Acta Gastroenterol. Belg. 1993; 56: 144.Nijevitch A.A., Shcherbakov P.L., Sataev V.U. et al. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy with nifuratel to furazolidone. Aliment. Pharmacol. Ther. 2005; 22: 881–887.Nijevitch A.A., Shcherbakov P.L., Sataev V.U. et al. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy with nifuratel to furazolidone. Aliment. Pharmacol. Ther. 2005; 22: 881–887.Dell′Anna A., Azzarone P., Ferrieri A. A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of Helicobacter pylori. Eur. Rev. Med. Pharmacol. Sci. 1999; 3: 105–110.Dell′Anna A., Azzarone P., Ferrieri A. A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of Helicobacter pylori. Eur. Rev. Med. Pharmacol. Sci. 1999; 3: 105–110.Gasbarrini A., Gasbarrini G., Pelosini I., Scarpignato C. Eradication of Helicobacter pylori: are rifaximin – based regimens effective. Digestion. 2006; 73 (Suppl. 1): 129–135.Gasbarrini A., Gasbarrini G., Pelosini I., Scarpignato C. Eradication of Helicobacter pylori: are rifaximin – based regimens effective. Digestion. 2006; 73 (Suppl. 1): 129–135.
The authors declare that there are no conflicts of interest present.